Approach to Sickle Cell Disease

Click for pdf: Approach to Sickle Cell Disease

Background

Definitions

• Worldwide, sickle cell disease is caused by one of the most common autosomal recessive gene defects.
• The wild type adult beta-chain hemoglobin is denoted as HbA.  The Sickle cell mutant beta-chain is denoted as HbS.
• The specific Sickle cell mutation is an Adenosine to Guanine substitution resulting in a substitution of hydrophobic valine for glutamic acid at position 6 of the beta-chain, reducing its solubility under deoxygenated conditions.
• Sickle cell anemia describes homozygosity for hemoglobin S (HbSS) while sickle cell disease describe all the conditions resulting from the phenomenon of sickling.

Background Physiology

• Sickle cell disease occurs when an affected individual inherits HbS from both parents and has the resultant genotype of HbSS.  It can also result when HbS from one parent is combined with another beta chain abnormality from the other parent, such as beta thalassemia or HbC.
• Heterozygous individuals have more than 50% normal hemoglobin and are typically asymptomatic.
• The Sickle cell mutation confers abnormal properties to the red blood cell.  When deoxygenated, the mutant hemoglobin polymerizes and distorts the RBC into a crescent or sickle shape with reduced deformability.  Adherence of the RBCs to the vascular endothelium results in the slowing of blood flow, vaso-occlusion of small vasculature and intimal hyperplasia.  Consequently, individuals are predisposed to ischemic damage to organs, painful crises, splenic dysfunction, growth retardation, hemolytic anemia and an increased vulnerability to infection (see table of clinical manifestations).
• With newborn screening offered for Sickle Cell Disease in most provinces in Canada, the diagnosis is usually made at birth, prior to the presence of symptoms. The first presentation of symptoms is usually with dactylitis (acute pain in hands and/or feet) and can occur, at any time during childhood (60 % by 2 years of life, 96% by 8 years of life).
• Overall survival of patients with Sickle Cell Disease is reduced but with advances in medical care survival is improving. Successful interventions include treatment with hydroxyurea (increases HbF production), antibiotics (considering functional asplenism) and more rapid care in cases of disease complications.
• Bone marrow transplant is the only curative treatment available.  The majority of treatments are aimed at reducing the frequency of painful crises and reducing their severity.

Questions to ask

a) Family History

Sickle cell is the most common single gene mutation afflicting individuals of African descent [1/375].  It is also common in those of Mediterranean, Turkish, Arabian and Indian descent.

b) Anemia

Excessive tiredness, fatigue, SOB, pallor

c) Pain crises

Acute painful episodes are the most common presentation of Sickle cell.

Persistent pain in bones, chest or abdomen

d) Signs of hypovolemia

Poor urine output, lack of tears, thirst

e) Acute chest syndrome

Cough, dyspnea, chest pain

f) Hand/ foot syndrome

Swollen and painful hands or feet

g) Stoke

Affects 10% of Sickle cell patients: sudden neurological deficits

h) Infection

Malaise, cough, chest pain, diarrhea, vomiting

i) Vaccinations

Children with Sickle cell are particularly prone to infection and should be immunized with the standard childhood regime plus 23-valent pneumococcus vaccine and an annual influenza vaccine. Meningococcal vaccine should be considered in adolescence.

j) Previous medical history

All patients with Sickle cell should be followed by a specialist clinic.  Therefore, these clinics should be used as an excellent source of information on disease severity, past manifestations and treatment regimens.

k) Diet

Adequate iron and folic acid due to high RBC turnover

l) Make sure to have patients avoid

Dehydration, overexertion and exposure to cold which increases the risk for vaso-occlusive crises.

Physical Examination

At every visit one should examine the following

Vitals

• Oxygen saturation, heart rate, respiratory rate, blood pressure and temperature

Growth parameters

• Growth delay and delay of sexual maturation is common

General Appearance

• Severe distress – Patients are at risk for serious presentations such as MI or stroke, chest crisis, bacteremia and sepsis which will require immediate intervention.

Abdominal exam

• Splenomegaly may be appreciated initially, after which the spleen size regresses

Skin

• Cyanosis
• Pallor of skin, lips or nail bed
• Ulcers
• Jaundice

Respiratory

• Signs of infection or edema

Ophthalmology

• Acuity
• Detailed retinal exam: neovascularization, detachment and “black sunburst” hemorrhages

MSK

• Inability to move extremities
• Painful swelling of hand and/or feet

Investigations

Laboratory investigations

Blood analysis: CBC. Chronic hemolysis associated with a mild anemia with reticulocytosis. That said, patients are at risk for acute severe anemia when the bone marrow supply does not meet demands, such as with an aplastic crisis (eg. parvovirus B19 infection) or with a splenic sequestration crisis.

Hemolysis studies: May see unconjugated hyperbilirubinemia, increased LDH, low haptoblobin.

Peripheral smear: reveals sickled red cells, polychromasia (reticulocytes), Howell Jolly bodies (signifies asplenism)

Hemoglobin studies: hemoglobin electrophoresis – HbF usually elevated

End organ damage: Kidney and Liver function

Bacterial cultures: if fever present

Urinanalysis: as part of septic workup, also to investigate kidney function, and the ability of kidney to concentrate urine

Imaging studies

Plain X-rays

Transcranial Doppler ultrasound or MRI to assess risk for/ diagnosis of stroke

Bone scan to differentiate bone pain from pain crises from that of osteomyelitis

Table: Major clinical manifestations in SCD

Differential diagnosis

• Rheumatic fever
• Septic arthritis
• Osteomyelitis
• Trauma
• Congenital syphilis
• Acute abdominal disorders
• Various severely painful medical conditions
• Drug seeking behavior

References

1. Wethers, D.  Sickle Cell Disease in Childhood: Part I. Laboratory Diagnosis, Pathophysiology and Health Maintenance.  AFP. Sept 1, 2000
2. Wethers, D.  Sickle Cell Disease in Childhood: Part II. Diagnosis and Treatment of Major Complications and Recent Advances in Treatment. AFP. Sept 15, 2000
3. Hoffman. Hematology: Basic Principles and Practice, 4^th ed. “Sickle cell”
4. First consult, version 13. “Sickle cell” Elsevier 2006
5. Elliott P Vichinsky. UpToDate. Overview of the clinical manifestations of sickle cell disease. March 2012

Acknowledgements

Writer: Giulio S. Dominelli

Editor: Elmine Statham